Literature DB >> 10871329

Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.

N Serkova1, B Hausen, G J Berry, W Jacobsen, L Z Benet, R E Morris, U Christians.   

Abstract

We report the tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD ¿40-O-(2-hydroxyethyl)-rapamycin and its metabolites in monkey lung transplant recipients as well as its interaction with cyclosporine as the Neoral formulation. After left unilateral lung transplantation, cynomolgus monkeys received by oral administration either 1) 1.5 mg/kg/day SDZ-RAD (n = 4); 2) 100 mg/kg/day cyclosporine (n = 4); 3) 0.3 mg/kg/day SDZ-RAD + 100 mg/kg/day cyclosporine (n = 6); 4) 1.5 mg/kg/day SDZ-RAD + 50 mg/kg/day cyclosporine (n = 5); or 5) SDZ-RAD and cyclosporine doses adjusted according to trough blood concentration measurements (n = 6). At the end of the observation period (usually 29 days after transplantation), and 24 h after the last doses, tissue samples were collected and analyzed with HPLC/mass spectrometry. Gall bladder, pancreas, the transplant lung, cerebellum, kidneys, and spleen had the highest SDZ-RAD concentrations. Coadministration of cyclosporine increased SDZ-RAD concentrations in most tissues as well as tissue-to-blood distribution coefficients. In contrast, SDZ-RAD had only a small effect on cyclosporine blood and tissue concentrations. Rejection in lung grafts in monkeys treated with either of the cyclosporine/SDZ-RAD combinations was significantly less than in the monotherapy groups (P <.002). Histological rejection scores were inversely correlated with SDZ-RAD concentrations in blood (r = -0. 68; P <.001; n = 24), lymph nodes (P = -0.58; P <.003; n = 24), thymus (r = -0.63; P <.001; n = 23) and transplant lung tissue (r = -0.58; P <.003; n = 24). We conclude that, in addition to the synergistic pharmacodynamic interaction, a pharmacokinetic interaction resulting in higher SDZ-RAD tissue concentrations contributed to the significantly better immunosuppressive efficacy when both drugs were combined compared with monotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871329

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice.

Authors:  Thomas Beresford; Tina Fay; Natalie J Serkova; Peter H Wu
Journal:  J Pharmacol Exp Ther       Date:  2012-02-28       Impact factor: 4.030

2.  Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.

Authors:  Jelena Klawitter; Sven Gottschalk; Carsten Hainz; Dieter Leibfritz; Uwe Christians; Natalie J Serkova
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

3.  Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment.

Authors:  Charles A Hoeffer; Helen Wong; Peter Cain; Josien Levenga; Kiriana K Cowansage; Yoon Choi; Camille Davy; Neil Majmundar; D Randy McMillan; Beverly A Rothermel; Eric Klann
Journal:  J Neurosci       Date:  2013-10-23       Impact factor: 6.167

4.  Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

Authors:  N Serkova; W Jacobsen; C U Niemann; L Litt; L Z Benet; D Leibfritz; U Christians
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 5.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

7.  The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.

Authors:  Finn Gustafsson; David Barth; Diego H Delgado; Meerna Nsouli; Jill Sheedy; Heather J Ross
Journal:  Eur J Clin Pharmacol       Date:  2009-05-21       Impact factor: 2.953

8.  Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats.

Authors:  Michael Deters; Gabriele Kirchner; Therese Koal; Klaus Resch; Volkhard Kaever
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

9.  Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury.

Authors:  Christopher J Sontag; Hal X Nguyen; Noriko Kamei; Nobuko Uchida; Aileen J Anderson; Brian J Cummings
Journal:  Stem Cells Transl Med       Date:  2013-08-27       Impact factor: 6.940

Review 10.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.